Along with the comprehensive data concerning our institutional experience on the use of rituximab for treatment of non-Hodgkin's lymphoma, we describe the first case of molecular remission induced by the chimeric anti-CD20 monoclonal antibody in a diffuse large cell lymphoma patient.
|Number of pages||2|
|Publication status||Published - 2000|
- Aggressive lymphoma
- Molecular remission
ASJC Scopus subject areas